OpenLB
Open Library of Bioscience
Advanced Search
Investigational new drugs
08, 2021;39 (4): 1011-1018.

Effects of rifampicin on the pharmacokinetics of alflutinib, a selective third-generation EGFR kinase inhibitor, and its metabolite AST5902 in healthy volunteers.

Yun-Ting Zhu, Yi-Fan Zhang, Jin-Fang Jiang, Yong Yang, Li-Xia Guo, Jing-Jing Bao, Da-Fang Zhong
Author Information
  1. Yun-Ting Zhu: State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 501 Haike Road, Shanghai, 201203, People's Republic of China.
  2. Yi-Fan Zhang: State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 501 Haike Road, Shanghai, 201203, People's Republic of China. yfzhang@simm.ac.cn.
  3. Jin-Fang Jiang: HQ Bioscience Co., LTD, Suzhou, People's Republic of China.
  4. Yong Yang: HQ Bioscience Co., LTD, Suzhou, People's Republic of China.
  5. Li-Xia Guo: State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 501 Haike Road, Shanghai, 201203, People's Republic of China.
  6. Jing-Jing Bao: Shanghai Allist Pharmaceuticals Co., Ltd, Shanghai, People's Republic of China.
  7. Da-Fang Zhong: State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 501 Haike Road, Shanghai, 201203, People's Republic of China. dfzhong@simm.ac.cn.
PMID: 33506323 DOI: 10.1007/s10637-021-01071-z

Abstract

Background Alflutinib is a novel irreversible and highly selective third-generation EGFR inhibitor currently being developed for the treatment of non-small cell lung cancer patients with activating EGFR mutations and EGFR T790M drug-resistant mutation. Alflutinib is mainly metabolized via CYP3A4 to form its active metabolite AST5902. Both alflutinib and AST5902 contribute to the in vivo pharmacological activity. The aim of this study was to investigate the effects of rifampicin (a strong CYP3A4 inducer) on the pharmacokinetics of alflutinib and AST5902 in healthy volunteers, thus providing important information for drug-drug interaction evaluation and guiding clinical usage. Methods This study was designed as a single-center, open-label, and single-sequence trial over two periods. The volunteers received a single dose of 80 mg alflutinib on Day 1/22 and continuous doses of 0.6 g rifampicin on Day 15-30. Blood sampling was conducted on Day 1-10 and Day 22-31. The pharmacokinetics of alflutinib, AST5902, and the total active ingredients (alflutinib and AST5902) with or without rifampicin co-administration were respectively analyzed. Results Co-administration with rifampicin led to 86% and 60% decreases in alflutinib AUC and C, respectively, as well as 17% decrease in AST5902 AUC and 1.09-fold increase in AST5902 C. The total active ingredients (alflutinib and AST5902) exhibited 62% and 39% decreases in AUC and C, respectively. Conclusions As a strong CYP3A4 inducer, rifampicin exerted significant effects on the pharmacokinetics of alflutinib and the total active ingredients (alflutinib and AST5902). The results suggested that concomitant strong CYP3A4 inducers should be avoided during alflutinib treatment. This trial was registered at http://www.chinadrugtrials.org.cn . The registration No. is CTR20191562, and the date of registration is 2019-09-12.

Keywords

AST5902 Alflutinib CYP3A4 Drug-drug interaction Rifampicin

References

Landre T, Des Guetz G, Chouahnia K, Duchemann B, Assié JB, Chouaid C (2020) First-line angiogenesis inhibitor plus erlotinib versus erlotinib alone for advanced non-small-cell lung cancer harboring an EGFR mutation. J Cancer Res Clin Oncol 146:3333–3339. https://doi.org/10.1007/s00432-020-03311-w [DOI: 10.1007/s00432-020-03311-w]
Chen JA, Riess JW (2020) Advances in targeting acquired resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors. J Thoracic Dis 12:2859–2876. https://doi.org/10.21037/jtd.2019.08.32 [DOI: 10.21037/jtd.2019.08.32]
Loong HH, Kwan SS, Mok TS, Lau YM (2018) Therapeutic strategies in EGFR mutant non-small cell lung cancer. Curr Treat Options in Oncol 19:58. https://doi.org/10.1007/s11864-018-0570-9 [DOI: 10.1007/s11864-018-0570-9]
Wecker H, Waller CF (2018) Afatinib. Recent Results Cancer Res 211:199–215. https://doi.org/10.1007/978-3-319-91442-8_14 [DOI: 10.1007/978-3-319-91442-8_14]
Li J, Kwok HF (2020) Current strategies for treating NSCLC: from biological mechanisms to clinical treatment. Cancers (Basel) 12:1587. https://doi.org/10.3390/cancers12061587 [DOI: 10.3390/cancers12061587]
Andrews Wright NM, Goss GD (2019) Third-generation epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer. Transl Lung Cancer Res 8:S247–S264. https://doi.org/10.21037/tlcr.2019.06.01 [DOI: 10.21037/tlcr.2019.06.01]
Lim ZF, Ma PC (2019) Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy. J Hematol Oncol 12:134. https://doi.org/10.1186/s13045-019-0818-2 [DOI: 10.1186/s13045-019-0818-2]
Santarpia M, Liguori A, Karachaliou N, Gonzalez-Cao M, Daffinà MG, D'Aveni A, Marabello G, Altavilla G, Rosell R (2017) Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy. Lung Cancer (Auckl) 8:109–125. https://doi.org/10.2147/lctt.s119644 [DOI: 10.2147/lctt.s119644]
Lamb YN, Scott LJ (2017) Osimertinib: a review in T790M-positive advanced non-small cell lung Cancer. Target Oncol 12:555–562. https://doi.org/10.1007/s11523-017-0519-0 [DOI: 10.1007/s11523-017-0519-0]
Shi Y, Zhang S, Hu X, Feng J, Ma Z, Zhou J, Yang N, Wu L, Liao W, Zhong D, Han X, Wang Z, Zhang X, Qin S, Ying K, Feng J, Fang J, Liu L, Jiang Y (2020) Safety, clinical activity, and pharmacokinetics of alflutinib (AST2818) in patients with advanced NSCLC with EGFR T790M mutation. J Thorac Oncol 15:1015–1026. https://doi.org/10.1016/j.jtho.2020.01.010 [DOI: 10.1016/j.jtho.2020.01.010]
Liu XY, Guo ZT, Chen ZD, Zhang YF, Zhou JL, Jiang Y, Zhao QY, Diao XX, Zhong DF (2020) Alflutinib (AST2818), primarily metabolized by CYP3A4, is a potent CYP3A4 inducer. Acta Pharmacol Sin 41:1366–1376. https://doi.org/10.1038/s41401-020-0389-3 [DOI: 10.1038/s41401-020-0389-3]
Liu X, Li W, Zhang Y, Jiang Y, Zhao Q, Zhong D (2019) Simultaneous determination of alflutinib and its active metabolite in human plasma using liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal 176:112735. https://doi.org/10.1016/j.jpba.2019.06.032 [DOI: 10.1016/j.jpba.2019.06.032]
US Food and Drug Administration: Center for Drug Evaluation and Research (CDER) (2020) Guidance for industry: clinical drug interaction studies-cytochrome P450 enzyme- and transporter-mediated drug interactions. US Food and Drug Administration
Shumaker RC, Aluri J, Fan J, Martinez G, Thompson GA, Ren M (2014) Effect of rifampicin on the pharmacokinetics of lenvatinib in healthy adults. Clin Drug Invest 34:651–659. https://doi.org/10.1007/s40261-014-0217-y [DOI: 10.1007/s40261-014-0217-y]
Luedtke D, Marzin K, Jungnik A, von Wangenheim U, Dallinger C (2018) Effects of ketoconazole and rifampicin on the pharmacokinetics of Nintedanib in healthy subjects. Eur J Drug Metab Pharmacokinet 43:533–541. https://doi.org/10.1007/s13318-018-0467-9 [DOI: 10.1007/s13318-018-0467-9]
Martin P, Oliver S, Robertson J, Kennedy SJ, Read J, Duvauchelle T (2011) Pharmacokinetic drug interactions with vandetanib during coadministration with rifampicin or itraconazole. Drugs R&D 11:37–51. https://doi.org/10.2165/11586980-000000000-00000 [DOI: 10.2165/11586980-000000000-00000]
Vishwanathan K, Dickinson PA, So K, Thomas K, Chen YM, De Castro Carpeno J, Dingemans AC, Kim HR, Kim JH, Krebs MG, Chih-Hsin Yang J, Bui K, Weilert D, Harvey RD (2018) The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib. Br J Clin Pharmacol 84:1156–1169. https://doi.org/10.1111/bcp.13534 [DOI: 10.1111/bcp.13534]
Elmeliegy M, Vourvahis M, Guo C, Wang DD (2020) Effect of P-glycoprotein (P-gp) inducers on exposure of P-gp substrates: review of clinical drug-drug interaction studies. Clin Pharmacokinet 59:699–714. https://doi.org/10.1007/s40262-020-00867-1 [DOI: 10.1007/s40262-020-00867-1]
Nishimura M, Koeda A, Suzuki E, Kawano Y, Nakayama M, Satoh T, Narimatsu S, Naito S (2006) Regulation of mRNA expression of MDR1, MRP1, MRP2 and MRP3 by prototypical microsomal enzyme inducers in primary cultures of human and rat hepatocytes. Drug Metab Dispos 21:297–307. https://doi.org/10.2133/dmpk.21.297 [DOI: 10.2133/dmpk.21.297]
Dickinson PA, Cantarini MV, Collier J, Frewer P, Martin S, Pickup K, Ballard P (2016) Metabolic disposition of Osimertinib in rats, dogs, and humans: insights into a drug designed to bind covalently to a cysteine residue of epidermal growth factor receptor. Drug Metab Dispos 44:1201–1212. https://doi.org/10.1124/dmd.115.069203 [DOI: 10.1124/dmd.115.069203]
Xu Y, Zhou Y, Hayashi M, Shou M, Skiles GL (2011) Simulation of clinical drug-drug interactions from hepatocyte CYP3A4 induction data and its potential utility in trial designs. Drug Metab Dispos 39:1139–1148. https://doi.org/10.1124/dmd.111.038067 [DOI: 10.1124/dmd.111.038067]
Dixit V, Moore A, Tsao H, Hariparsad N (2016) Application of micropatterned cocultured hepatocytes to evaluate the inductive potential and degradation rate of major xenobiotic metabolizing enzymes. Drug Metab Dispos 44:250–261. https://doi.org/10.1124/dmd.115.067173 [DOI: 10.1124/dmd.115.067173]

MeSH Term

Adolescent
Adult
Area Under Curve
Cytochrome P-450 CYP3A
Cytochrome P-450 CYP3A Inducers
Drug Interactions
ErbB Receptors
Female
Humans
Indoles
Male
Middle Aged
Protein Kinase Inhibitors
Pyridines
Pyrimidines
Rifampin
Young Adult

Chemicals

AST5902
Cytochrome P-450 CYP3A Inducers
Indoles
Protein Kinase Inhibitors
Pyridines
Pyrimidines
aflutinib
Cytochrome P-450 CYP3A
CYP3A4 protein, human
EGFR protein, human
ErbB Receptors
Rifampin
Clinical Trial, Phase I Journal Article Research Support, Non-U.S. Gov't

Word Cloud

Similar Articles

Cited By